Primary Hepatocyte Market Size, Growth & Forecast to 2032

Market Overview:

The primary hepatocyte market is on track for substantial growth, with a projected increase from USD 248.13 million in 2023 to USD 4859.25 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 6.48%. This growth is primarily driven by the rising prevalence of liver diseases, including hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD). The demand for advanced drug discovery and development processes is fueling the use of primary hepatocytes for in vitro testing and modeling, given their ability to provide a more realistic representation of human liver function compared to traditional cell lines.

Pharmaceutical and biotechnology companies are increasingly focusing on improving the efficiency and accuracy of drug discovery pipelines, making primary hepatocytes a valuable tool. Their application allows for better assessment of drug metabolism, toxicity, and efficacy. Furthermore, technological advancements in hepatocyte isolation and culture techniques are enhancing the viability and functionality of these cells, contributing to their increased use in drug discovery studies.

Emerging trends in the market include the utilization of bioprinting technologies to create 3D liver models, offering a more physiologically relevant platform for drug testing. Additionally, advancements in cryopreservation techniques are improving the storage and transportation of primary hepatocytes, enhancing accessibility, and reducing the limitations associated with fresh cell isolation procedures. The market is witnessing a growing emphasis on ethical sourcing practices and standardized protocols for primary hepatocyte isolation and culture, ensuring quality, consistency, and ethical procurement.

Opportunities for market players lie in the development of improved isolation and culture techniques, offering a broader range of primary hepatocytes, including cryopreserved cells and patient-derived options. Strategic partnerships with contract research organizations (CROs) and pharmaceutical companies can provide valuable insights and facilitate the development of targeted solutions for drug discovery applications. Proactive engagement with regulatory bodies and adherence to ethical sourcing practices will be crucial for ensuring the long-term sustainability of the primary hepatocyte market.

Market Drivers:

Factors such as unhealthy lifestyles, obesity, and increased alcohol consumption contribute to the rise in these diseases, creating a heightened demand for effective treatment options and intensifying drug discovery efforts. Primary hepatocytes play a pivotal role in these efforts, serving as a critical tool for researchers to assess the efficacy and safety of potential drugs for liver diseases, thereby propelling market growth.

The pharmaceutical industry's relentless pursuit of innovation in drug discovery and development is a primary driver for the growing demand for primary hepatocytes. These cells closely replicate human liver functions and metabolism, offering researchers a dependable platform for evaluating potential drug interactions with the liver and predicting their efficacy and safety in humans. The limitations of traditional testing methods, such as animal models and cell lines, further highlight the importance of primary hepatocytes as a more reliable and human-relevant alternative.

The increasing focus on personalized medicine is another significant catalyst for the primary hepatocyte market. These cells facilitate the study of individual patient responses to specific drugs, paving the way for the development of personalized treatment options for liver diseases.

Technological advancements in the culture and cryopreservation of hepatocytes are improving the viability and functionality of primary hepatocytes, making them more readily available for research and development purposes. This leads to a more efficient and reliable supply chain, further supporting market growth.

Government support, recognizing the substantial burden of liver diseases and increasing funding for related research, is providing a favorable environment for the primary hepatocyte market. Governments worldwide are dedicating resources to support research initiatives that utilize primary hepatocytes, aiding in the market's growth acceleration.

Furthermore, the expanding applications of primary hepatocytes in regenerative medicine, especially in cell transplantation therapies for liver cell replacement, are expected to contribute to the market's upward trajectory as regenerative medicine continues to advance.

Market Trends:

Rising Demand for In Vitro Drug Discovery

The in vitro diagnostics (IVD) market size worldwide was over 18 percent of the total global revenue in the medical technology industry in 2021.  During the COVID-19 pandemic, Europe saw massive investment in IVD testing to scale up capacity and cope with historic demand.

Advancements in Hepatocyte Isolation and Culture Techniques

With the onset of the 20th century, hepatocyte culture witnessed immense advancements, such as spheroid cultures, matrigel cultures, tissue engineering-based scaffolds, and 3D bio-printing to maintain long-term functional hepatocytes in vitro.  Cryopreservation of hepatocytes has increased due to the improvement of freezing and thawing methods.

Focus on Personalized Medicine and Precision Medicine

Precision medicine, also referred to as personalized medicine, helps physicians identify a patient’s unique disease risks and the treatments that will work best for them. - Primary human hepatocytes are still considered the “gold standard” for evaluating in vitro liver disease models.

Growing Investment in Liver Disease Research

The increasing prevalence of liver diseases such as hepatitis and non-alcoholic fatty liver disease (NAFLD) is driving investment in research efforts. Primary hepatocytes play a crucial role in these research activities, facilitating the exploration of disease mechanisms and the development of new therapies.

Market Restraints and Challenges:

• Limited Availability and Donor Variability: Primary hepatocytes are isolated from human livers, making their availability a major challenge. Donor livers are scarce, often obtained from surgical resections or deceased donors with limited suitability for cell isolation. Additionally, inherent variability exists between donors in terms of age, health status, and ethnicity. This variability can significantly impact the functionality and performance of isolated hepatocytes, affecting research results and downstream applications.
• High Cost and Complex Isolation Procedures: Isolating primary hepatocytes is a complex and labor-intensive process requiring specialized expertise and facilities. This complexity translates to high production costs, making these cells an expensive resource for researchers and pharmaceutical companies. Additionally, the viability and functionality of isolated hepatocytes diminish over time in culture, necessitating frequent isolation procedures, further adding to the overall cost burden.
• Limited Proliferation and Short Lifespan: Unlike some other cell types, primary hepatocytes have a limited capacity for self-renewal and proliferation in culture. This restricts the availability of sufficient cell numbers for large-scale studies and drug discovery applications. Furthermore, primary hepatocytes have a relatively short lifespan in culture, typically lasting only a few days to a few weeks. This limited lifespan poses challenges for long-term studies and drug screening assays.
• Ethical Considerations and Regulatory Hurdles: The use of human tissues for research purposes raises ethical concerns that require careful consideration and adherence to strict regulations. Obtaining informed donor consent, ensuring proper donor anonymity, and complying with bioethical guidelines add complexity to the procurement process. Additionally, regulatory requirements for handling and transporting human-derived tissues can further complicate research activities.
• Competition from Alternative In Vitro Models: The limitations associated with primary hepatocytes are driving the development and adoption of alternative in vitro models for drug discovery and liver disease research. These alternatives include immortalized human liver cell lines, stem cell-derived hepatocytes, and microfluidic organ-on-a-chip platforms. While these models may not fully replicate the functionality of primary hepatocytes, they offer advantages like scalability, lower costs, and potentially longer lifespans in culture.

Recent Developments:

• In August 2023, The recent announcement by the business indicates that the Phase III LITESPARK-005 research demonstrated that Merck's Welireg (belzutifan) successfully achieved its primary objective of a significant enhancement in progression-free survival for patients diagnosed with advanced renal cell carcinoma.
• In March 2023, Thermo Fisher Scientific established a cell therapy facility at UCSF to expedite the advancement of innovative therapeutic interventions. The anticipated collaboration between Thermo Fisher and UCSF in 2021 presented an opportunity to explore the hypothesis that the proximity of scientists, doctors, and patients to a manufacturing facility could enhance the efficiency of breakthrough drug development.

Segmentation Analysis:

Application:

• Drug Discovery and Development: The largest application segment for primary hepatocytes. These cells are used for in vitro drug metabolism and toxicity studies, playing a crucial role in identifying and developing new drugs with minimal side effects.
• Toxicity Testing: Primary hepatocytes are employed to assess the potential hepatotoxic (liver-damaging) effects of drugs, chemicals, and other substances. This helps ensure the safety of these products before human trials.
• Liver Disease Modeling and Research: Primary hepatocytes are vital tools for researchers studying liver diseases like hepatitis, cirrhosis, and fatty liver disease. They allow scientists to model disease processes and test potential therapeutic interventions.
• Regenerative Medicine: A growing application area with the potential to use primary hepatocytes for liver cell transplantation therapies to treat patients with end-stage liver disease.

Segments:

By Product

• Cryopreserved Suspension Hepatocytes
• Fresh suspension hepatocytes
• 3D (spheroid) hepatocytes
• Expanded Hepatocytes (Plateable)
• Non-characterized Hepatocytes

By Species

• Humans
• Rats
• Mice
• Dogs
• Monkeys
• Horses
• Others

By Application/Assay

• Cell Viability Assays
• Cytochrome Enzyme Activity
• High-content cytotoxicity
• Transporter Inhibition Assays
• In Vitro Intrinsic Clearance
• Phospholipids Assays
• Others

By End User

• Biopharmaceutical Companies
• Academic and Research Institutes
• Contract Research Organizations

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • The U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Key player:

• Thermo Fisher Scientific, Inc.
• Merck KgAa
• Corning Incorporated
• Lonza Group
• Charles River Laboratories, Inc.
• PromoCell Gmbh
• American Type Culture Collection (ATCC)
• Cell Biologics, Inc.
• Zen-Bio, Inc.
• Stemcell Technologies, Inc.
• AllCells
• iXCells Biotechnologies
• Neuromics
• Axol Bioscience Ltd.
• StemExpress
• Bioivt
• ScienCell Research Laboratories, Inc.
• AMSBIO
• ProMab Biotechnologies, Inc.
• Creative Bioarray
• Bps Bioscience, Inc.
• Epithelix
• Reachbio Research Labs
• AcceGen
• Kosheeka

Regional Analysis:

North America, currently the leader in the primary hepatocyte market, maintains its dominant position owing to several factors. These include an established research infrastructure with a concentration of pharmaceutical and biotechnology companies, high government funding for liver disease research, and an increasing adoption of primary hepatocytes in drug discovery and development. Europe, a strong contender, is expected to retain a robust market presence due to the presence of leading life science research centers, a growing focus on personalized medicine, and in vitro toxicology testing. Additionally, stringent regulatory requirements for drug development drive the demand for high-quality primary hepatocytes in the region.

Asia-Pacific emerges as an emerging market and is anticipated to be the fastest-growing regional market. This growth is attributed to rising disposable income, increasing investments in healthcare infrastructure, a growing burden of liver diseases in the region, and government initiatives promoting domestic research and development activities. The rest of the world, encompassing Latin America, the Middle East, and Africa, holds promising potential for future growth. Factors contributing to this potential include growing awareness of liver diseases, increasing investments in the healthcare sector, and the development of biobanking facilities to improve access to primary hepatocytes.

Future Outlook:

• Rising Demand for Drug Discovery and Development: The increasing prevalence of chronic liver diseases and the growing focus on personalized medicine will propel the demand for primary hepatocytes in drug discovery and development processes.
• Expanding Applications in Liver Disease Modeling: Advancements in 3D cell culture technologies and microfluidic systems will create new avenues for utilizing primary hepatocytes in liver disease modeling and drug screening, further accelerating market growth.
• Growing Adoption in Toxicity Testing: The rising need for reliable and efficient preclinical toxicity testing is expected to drive the adoption of primary hepatocytes as a viable alternative to traditional methods.
• Government Funding and Support: Continued government funding initiatives for liver research and drug discovery programs will provide a significant boost to the primary hepatocyte market.
• Increasing Focus on Personalized Medicine: The growing emphasis on personalized medicine approaches, including cell-based therapies, is likely to create new opportunities for the utilization of primary hepatocytes in regenerative medicine applications.
• Technological Advancements and Improved Isolation Techniques: Advancements in isolation and cryopreservation techniques will enhance the viability and functionality of primary hepatocytes, making them a more attractive option for research applications.
• Growing Awareness of Liver Diseases: Rising public awareness of liver diseases like hepatitis and non-alcoholic fatty liver disease (NAFLD) will likely fuel the demand for improved diagnostic tools and treatment options, ultimately benefiting the primary hepatocyte market.
• Strategic Collaborations and Mergers and Acquisitions: The market is expected to witness an increase in strategic collaborations and mergers and acquisitions between key players to expand product portfolios and geographical reach.
• Focus on Standardization and Regulatory Landscape: Regulatory bodies worldwide are likely to implement stricter guidelines and standardization protocols for primary hepatocytes, ensuring their quality and consistency for research purposes.
• Regional Market Expansion: The Asia Pacific region is expected to experience the fastest growth in the primary hepatocyte market due to factors like rising government investments in healthcare infrastructure and increasing research activities.